Brief: Teva Expands European Biosimilars Portfolio With Launch Of AHZANTIVE Biosimilar To Eylea
04/06/2026 13:31
BRIEF-Teva Expands European Biosimilars Portfolio With Launch Of AHZANTIVE Biosimilar To Eylea June 4 (Reuters) - Teva Pharmaceutical Industries Limited.. TEVA.TA:
TEVA EXPANDS EUROPEAN BIOSIMILARS PORTFOLIO WITH LAUNCH OF AHZANTIVE® (AFLIBERCEPT) BIOSIMILAR TO EYLEA®
TEVA - EXPECTS TO LAUNCH AHZANTIVE IN MORE MARKETS LATER IN 2026
Source text: ID:nGNX8wBPTw
Further company coverage: TEVA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Teva Pharmaceutical Industries..
See all newsBrief: Teva Expands European Biosimilars Portfolio With Launch Of AHZANTIVE Biosimilar To Eylea
US appeals court revives Amarin heart-drug patent lawsuit over Hikma generic - June 25, 2024
Teva hits over two-month high as branded drugs boost quarterly profit
Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand (updated)
Israel's Teva Q1 revenue and adjusted EPS beat estimates